Unique ID issued by UMIN | UMIN000000650 |
---|---|
Receipt number | R000000784 |
Scientific Title | Efficacy of sivelestat sodium administration in perioperative care of abdominal aortic aneurysm with pulmonary function disorder |
Date of disclosure of the study information | 2007/05/01 |
Last modified on | 2011/04/15 00:21:20 |
Efficacy of sivelestat sodium administration in perioperative care of abdominal aortic aneurysm with pulmonary function disorder
sivelestat sodium and abdominal aortic aneurysm
Efficacy of sivelestat sodium administration in perioperative care of abdominal aortic aneurysm with pulmonary function disorder
sivelestat sodium and abdominal aortic aneurysm
Japan |
abdominal aortic aneurysm
Vascular surgery |
Others
NO
to evaluate the efficacy of sivelestat sodium administration in perioperative care of abdominal aortic aneurysm with pulmonary function disorder.
Efficacy
Confirmatory
Pragmatic
Phase II
incidence of postoperative complications, lung injury score, duration of SIRS
mortality rate, in-hospital days, period in ICU, mechanical ventilation period, each cytokines
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
NO
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
Medicine |
intervention group: 4.8mg/kg of sivelestat sodium is dissolved in 50ml of saline and is continuously injected intravenously for 24 hours. The continuous injection is started during
the operation and will be continued for at least 5 days (until 4 POD).
control group(placebo group): 50ml of saline is continuously injected intravenously for 24 hours. The continuous injection is started during the operation and will be continued for at least 5 days (until 4 POD).
20 | years-old | <= |
Not applicable |
Male and Female
The participants should be over 20 years old and should have written consent to participate in the trial.
Patients with the P/F ratio of less than 300mmHg and the chest X-ray showing bilateral infiltration shadow during the operation will be included in the trial, because at the moment, administration of sivelestat sodium is covered by the insurance only for patients with the acute lung injury.
Cases matching following conditions are excluded from the trial.
(1)Patients allergic to the components of sivelestat sodium.
(2)Patients who are pregnant, have a possibility of pregnancy, and breast-feeding.
(3)Patients with evidence of high left atrium pressure.
(4)Cases that are considered not eligible for the trial by the doctor in charge.
(5)Patients without pulmonary function disorder, meaning patients with the P/F ratio of more than 300 and the chest X-ray that does not show bilateral infiltration shadow during the operation.
40
1st name | |
Middle name | |
Last name | Matsumoto Kenji |
Keio University, School of Medicine
Department of Surgery
Shinjukuku Shinanomachi 35, Tokyo
03-3353-1211(62334)
1st name | |
Middle name | |
Last name | Obara Hideaki |
Keio University, School of Medicine
Department of Surgery
Shinjukuku Shinanomachi 35, Tokyo
03-3353-1211(62334)
obara@sc.itc.keio.ac.jp
Keio University, School of Medicine
Department of Surgery
none
Self funding
none
none
NO
2007 | Year | 05 | Month | 01 | Day |
Unpublished
Completed
2007 | Year | 01 | Month | 29 | Day |
2007 | Year | 05 | Month | 01 | Day |
2009 | Year | 12 | Month | 01 | Day |
2010 | Year | 03 | Month | 01 | Day |
2010 | Year | 03 | Month | 01 | Day |
2011 | Year | 12 | Month | 01 | Day |
2007 | Year | 03 | Month | 23 | Day |
2011 | Year | 04 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000784